Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Charlotte I. Stroes"'
Autor:
Charlotte I. Stroes, Sybren L. Meijer, Geert-Jan Creemers, Gerrit K.J. Hooijer, Nadia Haj Mohammad, Maartje Los, Marije Slingerland, Geke A.P. Hospers, Annemieke Cats, Laurens V. Beerepoot, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Publikováno v:
Translational Oncology, Vol 49, Iss , Pp 102079- (2024)
Background: HER2 targeting in esophageal adenocarcinoma (EAC) has shown potential, but often fails to show durable response. Given the contributions of the tumor immune microenvironment (TIME) to therapeutic responses, we aimed to chart the TIME char
Externí odkaz:
https://doaj.org/article/140bcec5bc5649c49d43672c34967d9a
Autor:
Charlotte I. Stroes, Sandor Schokker, Remco J. Molenaar, Ron A. A. Mathôt, Maarten F. Bijlsma, Stephanie O. van der Woude, João P. Belo Pereira, Gerrit K. J. Hooijer, Rob H. A. Verhoeven, Annemieke Cats, Cecile Grootscholten, Johanna W. van Sandick, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Nadia Haj Mohammad, Jelle P. Ruurda, Sybren L. Meijer, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Hanneke W. M. van Laarhoven
Publikováno v:
Cancers, Vol 13, Iss 4, p 839 (2021)
We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m
Externí odkaz:
https://doaj.org/article/a57b8292324f4ddea0751775c1462862
Autor:
Sandor Schokker, Stephanie O. van der Woude, Jessy Joy van Kleef, Daan J. van Zoen, Martijn G. H. van Oijen, Banafsche Mearadji, Ludo F. M. Beenen, Charlotte I. Stroes, Cynthia Waasdorp, R. Aarti Jibodh, Aafke Creemers, Sybren L. Meijer, Gerrit K. J. Hooijer, Cornelis J. A. Punt, Maarten F. Bijlsma, Hanneke W. M. van Laarhoven
Publikováno v:
Cancers, Vol 11, Iss 6, p 827 (2019)
First-line triplet chemotherapy including a taxane may prolong survival in patients with metastatic esophagogastric cancer. The added toxicity of the taxane might be minimized by using nab-paclitaxel. The aim of this phase I study was to determine th
Externí odkaz:
https://doaj.org/article/85c862f5975845cb858633c82373ad62
Autor:
Madelaine G. van Mackelenbergh, Charlotte I. Stroes, René Spijker, Casper H.J. van Eijck, Johanna W. Wilmink, Maarten F. Bijlsma, Hanneke W.M. van Laarhoven
Publikováno v:
Cancers, Vol 11, Iss 5, p 588 (2019)
The tumor microenvironment plays an important role in the initiation and progression of pancreatic adenocarcinoma (PDAC). In this systematic review, we provide an overview of clinical trials with stroma-targeting agents. We systematically searched ME
Externí odkaz:
https://doaj.org/article/22d4c9b62a9c4714bda8a6bebfdbfdc6
Autor:
Charlotte I Stroes, Sandor Schokker, Mohammed Khurshed, Stephanie O van der Woude, Ron AA Mathôt, Marije Slingerland, Judith de Vos-Geelen, Massimo Zucchetti, Cristina Matteo, Erik van Dijk, Bauke Ylstra, Victor Thijssen, Sarah Derks, Tesfay Godefa, Willemieke Dijksterhuis, Gerben E Breimer, Otto M van Delden, Rob HA Verhoeven, Sybren L Meijer, Maarten F Bijlsma, Hanneke WM van Laarhoven
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 14 (2022)
Purpose: Regorafenib monotherapy, a multikinase inhibitor of angiogenesis, tumor microenvironment, and tumorigenesis, showed promising results in gastric cancer. We aimed to assess the tolerability of regorafenib and paclitaxel in patients with advan
Externí odkaz:
https://doaj.org/article/aed72a810b8b46b7a7487a5ebbe32545
Autor:
Daniela Kolarevic Ivankovic, Rob H.A. Verhoeven, Suthinee Ithimakin, Jorge Barriuso, Antonio Calles, Ivana Bozovic-Spasojevic, Charlotte I. Stroes, Martijn G H van Oijen, Carlos Gomez-Roca, Andrew Furness, Wan-Ling Tan, Willemieke P M Dijksterhuis, H. Laarhoven, Sjoukje F. Oosting
Publikováno v:
International Journal of Cancer
Dijksterhuis, W P M, Stroes, C I, Tan, W-L, Ithimakin, S, Calles, A, van Oijen, M G H, Verhoeven, R H A, Barriuso, J, Oosting, S F, Korarevic Ivankovic, D, Furness, A J S, Bozovic-Spasojevic, I, Gomez-Roca, C & van Laarhoven, H W M 2019, ' From presentation to paper: gender disparities in oncological research ', International Journal of Cancer . https://doi.org/10.1002/ijc.32660
International Journal of Cancer, 37(15). Wiley
International journal of cancer. Journal international du cancer, 146(11), 3011-3021. Wiley-Liss Inc.
Dijksterhuis, W P M, Stroes, C I, Tan, W-L, Ithimakin, S, Calles, A, van Oijen, M G H, Verhoeven, R H A, Barriuso, J, Oosting, S F, Korarevic Ivankovic, D, Furness, A J S, Bozovic-Spasojevic, I, Gomez-Roca, C & van Laarhoven, H W M 2019, ' From presentation to paper: gender disparities in oncological research ', International Journal of Cancer . https://doi.org/10.1002/ijc.32660
International Journal of Cancer, 37(15). Wiley
International journal of cancer. Journal international du cancer, 146(11), 3011-3021. Wiley-Liss Inc.
Gender disparities in scientific publications have been identified in oncological research. Oral research presentations at major conferences enhance visibility of presenters. The share of women presenting at such podia is unknown. We aim to identify
Autor:
Gerrit K. J. Hooijer, Sandor Schokker, Maarten C.C.M. Hulshof, Sybren L. Meijer, Charlotte I. Stroes, Stephanie O. van der Woude, Nadia Haj Mohammad, Cecile Grootscholten, Remco J. Molenaar, Mark I. van Berge Henegouwen, Jelle P Ruurda, Hanneke W. M. van Laarhoven, Ron A. A. Mathôt, Geert-Jan Creemers, Grard A. P. Nieuwenhuijzen, Rob H.A. Verhoeven, Johanna W. van Sandick, Annemieke Cats, Maarten F. Bijlsma, João P. Belo Pereira
Publikováno v:
Cancers
Volume 13
Issue 4
Cancers, Vol 13, Iss 839, p 839 (2021)
Cancers, 13(4):839, 1-15. Multidisciplinary Digital Publishing Institute (MDPI)
Stroes, C I, Schokker, S, Molenaar, R J, Mathôt, R A A, Bijlsma, M F, van der Woude, S O, Pereira, J P B, Hooijer, G K J, Verhoeven, R H A, Cats, A, Grootscholten, C, van Sandick, J W, Creemers, G-J, Nieuwenhuijzen, G A P, Mohammad, N H, Ruurda, J P, Meijer, S L, Hulshof, M C C M, Henegouwen, M I V B & van Laarhoven, H W M 2021, ' A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox ', Cancers, vol. 13, no. 4, 839, pp. 1-15 . https://doi.org/10.3390/cancers13040839
Volume 13
Issue 4
Cancers, Vol 13, Iss 839, p 839 (2021)
Cancers, 13(4):839, 1-15. Multidisciplinary Digital Publishing Institute (MDPI)
Stroes, C I, Schokker, S, Molenaar, R J, Mathôt, R A A, Bijlsma, M F, van der Woude, S O, Pereira, J P B, Hooijer, G K J, Verhoeven, R H A, Cats, A, Grootscholten, C, van Sandick, J W, Creemers, G-J, Nieuwenhuijzen, G A P, Mohammad, N H, Ruurda, J P, Meijer, S L, Hulshof, M C C M, Henegouwen, M I V B & van Laarhoven, H W M 2021, ' A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox ', Cancers, vol. 13, no. 4, 839, pp. 1-15 . https://doi.org/10.3390/cancers13040839
We assessed the feasibility of adjuvant S-1 and oxaliplatin following neoadjuvant chemoradiotherapy (nCRT) and esophagectomy. Patients treated with nCRT (paclitaxel, carboplatin) and esophagectomy received six 21-day cycles with oxaliplatin (130 mg/m
Autor:
Stephanie O. van der Woude, Roel J. Bennink, Ron A. A. Mathôt, Mark I. van Berge Henegouwen, Geke A. P. Hospers, Charlotte I. Stroes, Martijn G.H. van Oijen, Maurice J.C. van der Sangen, Maartje Los, Geert Jan Creemers, Annemieke Cats, Maarten F. Bijlsma, Sandor Schokker, Maarten C.C.M. Hulshof, Sybren L. Meijer, Hanneke W. M. van Laarhoven, Kausilia K. Krishnadath, Rob H.A. Verhoeven, Remco J. Molenaar, Grard A. P. Nieuwenhuijzen, Laurens V. Beerepoot, Cornelis J. A. Punt, Joos Heisterkamp, Marije Slingerland, Aafke Creemers
Publikováno v:
Journal of Clinical Oncology, 38(5), 462-471. American Society of Clinical Oncology
Journal of clinical oncology, 38(5), 462-471. American Society of Clinical Oncology
Stroes, C I, Schokker, S, Creemers, A, Molenaar, R J, Hulshof, M C C M, van der Woude, S O, Bennink, R J, Mathôt, R A A, Krishnadath, K K, Punt, C J A, Verhoeven, R H A, van Oijen, M G H, Creemers, G J, Nieuwenhuijzen, G A P, van der Sangen, M J C, Beerepoot, L V, Heisterkamp, J, Los, M, Slingerland, M, Cats, A, Hospers, G A P, Bijlsma, M F, van Berge Henegouwen, M I, Meijer, S L & van Laarhoven, H W M 2020, ' Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma : Trap study ', Journal of Clinical Oncology, vol. 38, no. 5, pp. 462-471 . https://doi.org/10.1200/JCO.19.01814
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(5):JCO1901814, 462-471. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(5), 462-471. AMER SOC CLINICAL ONCOLOGY
J Clin Oncol
Journal of clinical oncology, 38(5), 462-471. American Society of Clinical Oncology
Stroes, C I, Schokker, S, Creemers, A, Molenaar, R J, Hulshof, M C C M, van der Woude, S O, Bennink, R J, Mathôt, R A A, Krishnadath, K K, Punt, C J A, Verhoeven, R H A, van Oijen, M G H, Creemers, G J, Nieuwenhuijzen, G A P, van der Sangen, M J C, Beerepoot, L V, Heisterkamp, J, Los, M, Slingerland, M, Cats, A, Hospers, G A P, Bijlsma, M F, van Berge Henegouwen, M I, Meijer, S L & van Laarhoven, H W M 2020, ' Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma : Trap study ', Journal of Clinical Oncology, vol. 38, no. 5, pp. 462-471 . https://doi.org/10.1200/JCO.19.01814
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 38(5):JCO1901814, 462-471. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(5), 462-471. AMER SOC CLINICAL ONCOLOGY
J Clin Oncol
PURPOSE Approximately 15% to 43% of esophageal adenocarcinomas (EACs) are human epidermal growth factor receptor 2 (HER2) positive. Because dual-agent HER2 blockade demonstrated a survival benefit in breast cancer, we conducted a phase II feasibility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22c9cfd388de41f0f13b5f3e8fd2b40e
https://research.vumc.nl/en/publications/4716be5e-05fb-49a2-9bc2-37c922f3ff70
https://research.vumc.nl/en/publications/4716be5e-05fb-49a2-9bc2-37c922f3ff70
Autor:
Johanna W. Wilmink, Charlotte I. Stroes, Maarten F. Bijlsma, Casper H.J. van Eijck, Madelaine G. van Mackelenbergh, René Spijker, Hanneke W. M. van Laarhoven
Publikováno v:
Cancers, 11(5):588. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
van Mackelenbergh, M G, Stroes, C I, Spijker, R, van Eijck, C H J, Wilmink, J W, Bijlsma, M F & van Laarhoven, H W M 2019, ' Clinical trials targeting the stroma in pancreatic cancer: A systematic review and meta-analysis ', Cancers, vol. 11, no. 5, 588 . https://doi.org/10.3390/cancers11050588
Cancers, Vol 11, Iss 5, p 588 (2019)
Cancers
van Mackelenbergh, M G, Stroes, C I, Spijker, R, van Eijck, C H J, Wilmink, J W, Bijlsma, M F & van Laarhoven, H W M 2019, ' Clinical trials targeting the stroma in pancreatic cancer: A systematic review and meta-analysis ', Cancers, vol. 11, no. 5, 588 . https://doi.org/10.3390/cancers11050588
Cancers, Vol 11, Iss 5, p 588 (2019)
The tumor microenvironment plays an important role in the initiation and progression of pancreatic adenocarcinoma (PDAC). In this systematic review, we provide an overview of clinical trials with stroma-targeting agents. We systematically searched ME
Autor:
Wietse J. Eshuis, Maarten C.C.M. Hulshof, Faridi S. van Etten-Jamaludin, Héctor G. van den Boorn, Hanneke W. M. van Laarhoven, Charlotte I. Stroes, Mirjam A. G. Sprangers, Aeilko H. Zwinderman
Publikováno v:
Critical Reviews in Oncology/Hematology. 154:103069
Surgery and chemoradiotherapy can potentially cure esophageal and gastric cancer patients, although they may impact health-related quality of life (HRQoL). We aim to systemically review and meta-analyze literature to determine the effect of curative